KYMR

Kymera Therapeutics Inc.

Price

$127.31

return (12m)

199.06%

p/e

-37.84

p/bv

7.51

DIVIDEND YIELD

0.00%

KYMR price

Kymera Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KYMR

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

14.22%

3 months

57.93%

1 year

199.06%

2 years

185.77%

5 years

137.16%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals KYMR

Valuation

P/E

-37.84

Sector -4.38

Industry -4.38

P/BV

7.51

Sector 2.02

Industry 2.02

P/Revenue (PSR)

107.98

Sector -4.40

Industry -4.40

EV/EBITDA

-180.15

Sector -263.09

Industry -263.09

EV/EBIT

-174.16

Sector -702.90

Industry -702.90

P/EBITDA

-38.96

Sector -4.39

Industry -4.39

P/EBIT

-37.88

Sector -4.73

Industry -4.73

P/Total Assets

6.89

Sector 1.49

Industry 1.49

P/Net Current Assets

18.86

Sector -11.70

Industry -11.70

P/Working Capital

17.03

Sector -3.19

Industry -3.19

EPS

-3.06

Sector -2.14

Industry -2.14

BVPS

15.40

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-90.92%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-94.05%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.04

Sector 0.03

Industry 0.03

Profitability

ROE

-19.85%

Sector -65.14%

Industry -65.14%

ROA

-18.21%

Sector -65.53%

Industry -65.53%

ROIC

-31.37%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

10.34

Sector 2.90

Industry 2.90

Net Debt / EBITDA

11.69

Sector -6.07

Industry -6.07

Net Debt / EBIT

11.30

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.46

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.92

Sector 0.41

Industry 0.41

Liabilities/Assets

0.08

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

7.59%

Sector -

Industry -

5Y Earnings CAGR

24.49%

Sector -

Industry -

Fundamentals KYMR

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KYMR Kymera Therapeutics Inc.	$127.31	191.86%	0.00%	-37.84	7.51	-19.85%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KYMR Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Kymera Therapeutics

Kymera Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2020

Time since IPO - 6 years

75

Employees

Kymera Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $11.34 billion, with shareholders equity totaling $1.51 billion.

The company employs approximately 75 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Kymera Therapeutics Inc. reported $105.00 million in revenue, generating net income of $-299.59 million.

Key financial metrics include a P/E ratio of -37.84, a price-to-book (P/B) ratio of 7.51, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KYMR.

Market cap

$11.34 billion

Net worth

$1.51 billion

$1,509,260,000.00

Assets

$1.65 billion

$1,645,440,000.00

Total Shares Outstanding

98.00 million

98,000,000

Average Daily Trading Volume

$911.06 Thousand

$911,056.00

Sector

Health Care

Industry

Biotechnology

KYMR

KYMR revenue and profits

Financial Results KYMR

DRAG THE FRAME TO SEE MORE DATA

KYMR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Kymera Therapeutics (KYMR) today?

A cotação de Kymera Therapeutics (KYMR) hoje está em US$ 127.31, com uma variação de 199.06% em relação ao último ano. A cotação de Kymera Therapeutics (KYMR) iniciou o ano negociando na casa dos US$ 77.81 e hoje está em US$ 127.31. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Kymera Therapeutics (KYMR) e dados de ações do Ibovespa e mercados internacionais.

Quando Kymera Therapeutics (KYMR) paga dividendos?

Kymera Therapeutics (KYMR) não distribuiu dividendos no último ano.

Is Kymera Therapeutics (KYMR) a good investment?

Atualmente, Kymera Therapeutics (KYMR) está cotada a US$ 127.31, com um P/L de -37.84, representando um desvio de -1,881% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 199.06 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 199.06%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Kymera Therapeutics (KYMR) stock?

Investir em ações de Kymera Therapeutics (KYMR) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Kymera Therapeutics (KYMR) yield today?

A rentabilidade de Kymera Therapeutics (KYMR) foi de 14.22% no último mês, 199.06% no último ano e 137.16% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Kymera Therapeutics (KYMR) hoje, o investimento total seria de US$ 12,731.00, com base na cotação atual de US$ 127.31.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 38,073.33
Em 5 anos: US$ 30,192.84
Em 10 anos: US$ 12,731.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KYMR

Kymera Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KYMR

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING KYMR WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Kymera Therapeutics

Kymera Therapeutics Inc.

United States

11 years

2020

75

PROFIT X PRICE KYMR

Financial Results KYMR

KYMR cash flow

Asset, Revenue and Profit Growth - KYMR

KYMR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions